
Jamie Dimon says JPMorgan Chase will get involved in stablecoins as fintech threat looms
It's the message Dimon gave Tuesday when asked during an earnings conference call about whether his company, the largest and most influential U.S. bank, was exploring the payment technology.
Stablecoins, as the name suggests, are a type of cryptocurrency designed to maintain a steady value that are usually pegged to a currency like the U.S. dollar. Last month, JPMorgan announced it will launch a more limited version of a stablecoin that only works for JPMorgan clients; a true stablecoin would presumably be more universally accepted.
"We're going to be involved in both JPMorgan deposit coin and stablecoins to understand it, to be good at it," Dimon said. "I think they're real, but I don't know why you'd want to [use a] stablecoin as opposed to just payment."
Dimon, 69, is one of the most vocal opponents of certain cryptocurrencies like bitcoin. But his bank is a juggernaut in the global payments industry, helping move nearly $10 trillion daily, and so it makes sense that they would explore stablecoins at a time when the regulatory framework for the technology has opened up.
Failing to do so could cede ground to fintech players who are looking to recreate elements of the regulated financial ecosystem, Dimon said on Tuesday.
"You know, these guys are very smart," Dimon said of his fintech competitors. "They're trying to figure out a way to create bank accounts, to get into payment systems and rewards programs, and we have to be cognizant of that. And the way to be cognizant is to be involved."
Bank of America CEO Brian Moynihan has also said his firm would get involved in stablecoins.
One way could be for traditional banks to collaborate through the jointly owned Early Warning Services. That would be similar to the way they banded together to offer Zelle for instant peer-to-peer payments as a way to defend turf against PayPal and Block's Cash App.
When asked on Tuesday about a possible collaboration among banks, Dimon declined to give a specific answer.
"That's a great question, and we'll leave it remaining as a question," Dimon said. "You can assume we're thinking about all that."

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Big banks are back. Here's why.
Big banks are starting to flex again — and one analyst said their stocks are the best place for investors to be in the second half of 2025. Following better-than-expected earnings from Goldman Sachs (GS), Bank of America (BAC), and Morgan Stanley (MS), Argus Research director of financial services research Stephen Biggar said the environment now favors big players with exposure to capital markets. "These big banks are actually gaining share," Biggar said on Yahoo Finance's Opening Bid. Major banks are showing strong investment banking results and positive loan growth, with average loans up 5% at JPMorgan (JPM) and 7% at Bank of America. Year to date, stocks of Goldman Sachs and JPMorgan are up 22% and 19%, respectively, handily beating the S&P 500's (^GSPC) 6% gain. Morgan Stanley and BoA are up 10% and 3%, respectively. That's a significant shift from earlier in the year, when many on Wall Street were bracing for sluggish growth and cautious outlooks tied to tariff-related turmoil. Bank executives had struck a more conservative tone, particularly around the pace of investment banking recovery, but the latest numbers reveal a more optimistic story. Biggar argued that big banks are pulling ahead of regional players, largely because of their scale, diversification, and ability to benefit from improving capital markets activity. "I think regionals are struggling a bit here," Biggar said, adding that large firms are better positioned because they can grow more by increasing loans and expanding their service areas. For example, JPMorgan is adding 500 branches over the next few years and has a wider array of products for the average consumer, Biggar said. There are also regulatory tailwinds that could develop under the Trump administration, including the prospect of lower capital requirements from the Federal Reserve, which could free up big banks to lend more aggressively. That would add to already strong momentum in key areas like credit cards and commercial lending. Bigger added that the deck is currently stacked in favor of firms involved in equity and debt underwriting, advisory services, and trading. Goldman Sachs, for example, posted strong investment banking results in Q2, thanks in part to rising M&A activity and a pickup in debt underwriting. JPMorgan and Morgan Stanley also showed strength in these areas, suggesting that deal activity is coming back to life. "There's a long runway ahead," he said. "We think there's a lot of pent-up demand in investment banking, more M&A activity, and an easier regulatory environment, which could mean the big banks would be the prime beneficiaries." While the news on big banks is solid, "the great news is on investment banking, and that's cyclical," Commerce Street Holdings CEO Dory Wiley said on Yahoo Finance's Market Catalysts. Wiley pointed to Huntington Bancshares' (HBAN) $1.9 billion acquisition of Veritex (VBTX) as a possible prelude to more regional bank consolidation across the US. "Investors are realizing this was priced in already," he said, noting that while some deal optimism is returning, "there's still a lot of pressure on the consumer." Francisco Velasquez is a Reporter at Yahoo Finance. He can be reached on LinkedIn and X, or via email at Click here for in-depth analysis of the latest stock market news and events moving stock prices Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 minutes ago
- Yahoo
JPMorgan Cuts Sarepta (SRPT) PT, Keeps Overweight Rating
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the 10 Best Small-Cap Stocks to Buy According to Billionaires. On July 10, JPMorgan lowered its price target for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) from $30 to $28 but kept an 'Overweight' rating. JPMorgan highlighted that there is a 'valuation disconnect' and the current stock price does not fully reflect the long-term value of the company's business. A laboratory technician in a white coat holding a microscope and examining a vial of biopharmaceuticals. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has three FDA-approved treatments for Duchenne Muscular Dystrophy (DMD) with amenable mutations. These treatments are known as Exondys 51, Vyondys 53, and Amondys 45. Additionally, JPMorgan analysts noted that the company's gene therapy, Elevidys, has full approval for use in all ambulatory DMD patients. The company's gene therapy Elevidys currently has full approval for all ambulatory DMD patients, according to JPMorgan. However, Elevidys still holds accelerated approval status while Sarepta Therapeutics, Inc. (NASDAQ:SRPT) continues discussions with the FDA. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a medical research and drug development company focused on developing precision genetic medicines for rare diseases. The company has leading positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs). While we acknowledge the potential of SRPT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Bloomberg
17 minutes ago
- Bloomberg
JPMorgan Is Now Worth More Than Three Largest Rivals Combined
JPMorgan Chase & Co. keeps putting more distance between itself and key rivals. The first half saw the bank's market value surpass that of its three largest competitors combined. It racked up $30 billion of profit in that period, more than double its closest rival, and widened its lead over Goldman Sachs Group Inc. and Morgan Stanley in investment-banking revenue.